Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.7721
+0.05087.04%
Pre-market: 0.7601-0.0120-1.55%09:22 EDT
Volume:2.88M
Turnover:2.11M
Market Cap:173.50M
PE:-1.59
High:0.7802
Open:0.7123
Low:0.6901
Close:0.7213
Loading ...

Penny Stock Sangamo (SGMO) Nosedives as Pfizer Terminates Partnership

TIPRANKS
·
31 Dec 2024

CompoSecure, Cemtrex And 3 Stocks To Watch Heading Into Tuesday

Benzinga
·
31 Dec 2024

24H | Faraday Future Soars Another 21%; BigBear.ai Jumps 2%; Sangamo Shares Plunge 60%

Tiger Newspress
·
31 Dec 2024

Sangamo decline on Pfizer collaboration decision ‘overdone’, says Barclays

TIPRANKS
·
31 Dec 2024

Barclays Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

TIPRANKS
·
31 Dec 2024

Stocks to Watch: Affinity Bancshares, Sangamo Therapeutics, CompoSecure

Dow Jones
·
31 Dec 2024

Sangamo Shares Plunge After Pfizer Ends Hemophilia A Gene Therapy Deal

Reuters
·
31 Dec 2024

Sangamo Therapeutics Shares Sinks After Pfizer Pulls Out of Potential Hemophilia A Therapy Study

MT Newswires Live
·
31 Dec 2024

BUZZ-Sangamo Therapeutics plunges after Pfizer terminates partnership

Reuters
·
31 Dec 2024

Sangamo down 31% at $1.61 after Pfizer decision to terminate collaboration

TIPRANKS
·
31 Dec 2024

Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

Reuters
·
31 Dec 2024

BRIEF-Sangamo Therapeutics To Regain Full Rights To Hemophilia A Gene Therapy Program Following Pfizer’S Decision To Cease Development Of Giroctocogene Fitelparvovec

Reuters
·
31 Dec 2024

Sangamo to regain rights to giroctocogene fitelparvovec from Pfizer

TIPRANKS
·
31 Dec 2024

Sangamo Therapeutics Inc: Collaboration and License Agreement With Pfizer Will Terminate Effective April 21, 2025

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics: Intends to Explore Options to Advance Program, Including Seeking Potential New Collaboration Partner

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics Inc: All Trial Participants Will Continue to Be Monitored as Planned During Transition Period

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics to Regain Full Rights to Hemophilia a Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

Business Wire
·
31 Dec 2024

Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
31 Dec 2024

Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Dec 2024